Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations.
Abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.012
Questions
- Â Â Â What is known about the combination of PARP inhibitors and abiraterone acetate plus prednisone in the treatment of patients with metastatic prostate cancer? (00:17-01:40)
- Â Â Â What were the aims, design and inclusion criteria of the MAGNITUDE study? (01:40-03:13)
- Â Â Â What were the efficacy and safety findings of the study and how did they differ in the cohorts with and without DNA repair defects? (03:14-06:09)
- Â Â Â What will be the challenges of incorporating PARP inhibitors into clinical practice in this patient population? (06:09-07:36)
Speaker Disclosure: Kim Chi discloses consultancy services for: Astellas, AstraZeneca, Daiichi Sankyo, Janssen, Macrogenics, Merck, Novartis, Pfizer, Point Biopharma, Roche and Sanofi. He discloses grant/research support from: Astellas, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche and Sanofi. He is a member of the advisory board for: Astellas, Astra Zeneca, Janssen, Merck, Novartis and Roche. He has received honoraria/honorarium from: AstraZeneca, Janssen and Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022
